Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

A

Activities of Daily Living (ADLs)
The basic self-care tasks people do every day — bathing, dressing, eating, using the toilet, and moving around. Doctors and caregivers often track ADLs to see how much support someone needs.
Advance directive
A legal document that states a person's wishes for medical care if they become unable to speak for themselves. It's worth setting up early, while someone with Alzheimer's can still clearly express their preferences.
Amyloid plaques
Clumps of a protein called beta-amyloid that build up between brain cells in Alzheimer's disease. They're one of the two hallmark changes seen in the brain (the other is tau tangles).
Anosognosia
When a person is genuinely unaware of their own memory or thinking problems — not denial, but the illness itself affecting their ability to notice the changes. It's common in Alzheimer's and can make it hard to convince someone they need help.
APOE (apolipoprotein E)
A gene that comes in a few variants. One variant, APOE e4, is linked to a higher chance of developing Alzheimer's — but having it doesn't mean someone will definitely get the disease, and not having it doesn't rule it out.

C

Caregiver burnout
Physical, emotional, and mental exhaustion from the ongoing demands of caregiving. It's common, it's not a personal failure, and it's a real reason to ask for respite care or support.
Cholinesterase inhibitor
A type of medication (examples include donepezil and rivastigmine) that can temporarily help with memory and thinking symptoms in some people with Alzheimer's. It doesn't stop the underlying disease.
Clinical trial
A research study that tests whether a new treatment is safe and whether it works, using real volunteers. Trials happen in phases, starting small (mostly testing safety) and growing larger (testing effectiveness) as a treatment shows promise.
Cognitive assessment (screening)
A short set of questions and tasks a doctor uses to check memory, attention, and thinking skills. It's a screening tool, not a diagnosis on its own — a positive result usually leads to further testing. The scales that studies report, such as the ADAS-Cog, MMSE and CDR-SB, are defined in the glossary of cognitive measures.

D

Delirium
A sudden, often short-term state of confusion, frequently caused by infection, medication, surgery, or dehydration. It can look like dementia but comes on quickly and is often reversible — which is why sudden confusion in an older adult should always be checked out.
Dementia
An umbrella term for a decline in memory or thinking severe enough to interfere with daily life. Alzheimer's disease is the most common cause of dementia, but not the only one.

E

Early-onset Alzheimer's
Alzheimer's disease that begins before age 65. It's less common than the typical late-onset form and is more likely to run in families.
Executive function
The mental skills used to plan, organize, make decisions, and manage time — like following a recipe or paying bills. Trouble with executive function is often an early sign of Alzheimer's, sometimes before memory problems become obvious.

F

Frontotemporal dementia
A group of dementias caused by damage to the front and side parts of the brain, often affecting personality, behavior, and language before memory. It tends to start at a younger age than Alzheimer's, often in the 40s to 60s.

H

Hospice care
Care focused on comfort, not cure, typically for someone expected to live six months or less. For advanced Alzheimer's, hospice can support both the patient and the family, often at home.

L

Lewy body dementia
A type of dementia caused by abnormal protein deposits (Lewy bodies) in the brain. It often includes visual hallucinations, fluctuating alertness, and movement symptoms similar to Parkinson's disease, alongside memory changes.

M

Memantine
A medication used for moderate to severe Alzheimer's that works differently from cholinesterase inhibitors. It's sometimes prescribed alongside them.
Mild Cognitive Impairment (MCI)
Noticeable memory or thinking changes that are more than typical aging but don't yet significantly interfere with daily independence. Some people with MCI go on to develop Alzheimer's; others stay stable or even improve. It's a stage worth monitoring closely with a doctor.

N

Neurodegeneration
The gradual loss of structure or function of brain cells, eventually leading to their death. It's the broad process underlying Alzheimer's and many other brain diseases.

P

PET scan (amyloid PET)
A brain imaging scan that can detect amyloid plaques directly in a living person's brain, using a special tracer. It's mainly used in research and specialist diagnosis, not routine screening.
Power of attorney
A legal document that lets a person name someone else to make decisions — financial, medical, or both — on their behalf. Best set up early, while the person with Alzheimer's can still participate in the decision.

R

Respite care
Short-term care that gives a family caregiver a planned break — anything from a few hours to a few weeks. It's a tool for preventing caregiver burnout, not a last resort.

S

Sundowning
A pattern of increased confusion, agitation, or restlessness in the late afternoon and evening, common in people with Alzheimer's. The exact cause isn't fully understood, but routine and light exposure can sometimes help.

T

Tau tangles
Twisted fibers of a protein called tau that build up inside brain cells in Alzheimer's disease, disrupting how the cells function. Along with amyloid plaques, they're one of the two hallmark brain changes in Alzheimer's.

V

Vascular dementia
Dementia caused by reduced blood flow to the brain, often after a stroke or from ongoing small-vessel damage. It's the second most common cause of dementia after Alzheimer's, and the two can occur together.

W

Wandering
When a person with dementia walks off and becomes lost or disoriented, even in familiar places. It's common and can be dangerous, so many families use ID bracelets, door alarms, or location devices as safeguards.

Biomarkers, scans and thinking tests

The measurements and tests behind most research summaries on this site: the proteins and scans that show what is happening in the brain, and the tests that show how a person is thinking.

Agnosia
Agnosia is the inability to recognize and identify objects or people using one or more of the senses, caused by brain damage from stroke, injury, dementia, or other neurological conditions. Failing to recognize something familiar does not necessarily mean the person's eyesight or general thinking is failing. The camera works and the picture arrives, but the label on it is gone.
Amyloid beta (Aβ)
Amyloid beta is a protein fragment that clumps together outside nerve cells to form the plaques seen in Alzheimer's disease. Its accumulation is one of the two changes required for a neuropathological diagnosis of Alzheimer's, and it begins building up years to decades before symptoms appear.
Amyloid PET
Amyloid PET uses a tracer such as florbetapir that binds to amyloid beta plaques, so the scanner can show how much plaque is in the brain. A positive scan is strong evidence that Alzheimer's pathology is present. Approved tracers reliably detect moderate-to-frequent plaque density but cannot reliably pick up sparse plaques, and a positive scan alone does not mean a person's symptoms are caused by Alzheimer's.
Aphasia
Aphasia is the loss of the ability to speak or to understand speech, caused by damage to the brain. In dementia it often starts as trouble finding words or naming familiar objects, and it is a problem with language, not with intelligence or hearing. The thought is fully formed; the word for it has gone missing from the shelf.
Apraxia
Apraxia is the loss of the ability to carry out skilled, learned movements on purpose, even though the muscles are strong enough and the person understands the request. A person may no longer be able to wink, lick their lips, or work through the steps of bathing or dressing. What people often get wrong: this is a brain-planning problem, not laziness, weakness, or refusal. The motor runs and the instructions exist, but the wiring between them has come loose.
AT(N) framework
AT(N) is a shorthand for grouping Alzheimer's biomarkers by what they measure: A for amyloid beta, T for tau, and (N) for neurodegeneration or neuronal injury. The 2024 Alzheimer's Association criteria extend it with I for inflammation, V for vascular brain injury, and S for alpha-synuclein, and they split tau into T1 (early-changing phosphorylated tau in blood or spinal fluid) and T2 (tau PET and later-changing tau measures). They also drop the earlier assumption that a scan and a fluid test in the same letter always mean the same thing. It is a scorecard with one column per suspect, so a clinician can say which protein problems are present rather than just naming the syndrome.
Atrophy
Atrophy is the wasting away or shrinking of cells, tissue, or organs. On a brain MRI in dementia it appears as shrunken tissue and widened spaces, and its pattern — which regions have shrunk most — gives clues about which disease is responsible.
Aβ42/40 ratio
The Aβ42/40 ratio compares two lengths of amyloid beta. As amyloid is deposited into plaques in the brain, the level of the stickier Aβ42 falls relative to Aβ40 in the fluid, so a lower ratio signals amyloid pathology. In the 2024 criteria the ratio is listed as a usable measure in cerebrospinal fluid; in blood the difference between the two is much smaller, which makes plasma Aβ42/40 harder to measure reliably. You cannot see the snow that has already settled on the roof, so you measure how much less is still falling through the air.
Biomarker
A biomarker is a biological sign of disease that can be measured in blood, other body fluids, or tissue, or seen on a scan. Biomarkers can indicate risk, help make a diagnosis, and track whether a disease is progressing.
Blood-based biomarker
A blood-based biomarker is an Alzheimer's marker measured from an ordinary blood draw rather than from a spinal tap or a PET scan. Their arrival is the biggest recent change in Alzheimer's diagnosis, because they make biological testing far more widely available. Accuracy varies a lot between assays, and the 2024 criteria are explicit that not all available tests are good enough for diagnostic use.
Centiloid scale
The Centiloid scale is a standardised way of expressing how much amyloid an amyloid PET scan shows, so that results from different scanners and tracers can be compared. It is anchored so that roughly 0 represents a typical amyloid-negative brain and 100 a typical mild Alzheimer's dementia brain. It is the accepted method for quantifying amyloid PET, though it was built around the pattern seen in ordinary late-onset Alzheimer's and may need adjustment in inherited or Down syndrome-related Alzheimer's.
Cerebrospinal fluid (CSF)
Cerebrospinal fluid is the clear liquid that surrounds the brain and spinal cord. It is sampled through a lumbar puncture (spinal tap) and can be tested for amyloid and tau markers. Because it bathes the brain directly, it reflects brain chemistry more closely than blood does.
Clinical Dementia Rating (CDR)
The CDR is a structured interview with both the person and someone who knows them well, rating six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The CDR Sum of Boxes (CDR-SB) adds the six scores, giving a scale from 0 to 18 where higher means more impairment. It is the main outcome measure in the recent anti-amyloid trials.
Cognitive reserve
Cognitive reserve is the idea that some brains cope better with a given amount of damage than others, so two people with the same amount of plaque and tangle can have very different symptoms. Education, complex work, and mentally and socially active lives are associated with greater reserve. It does not prevent the underlying disease — it changes how long the disease stays hidden. Two bridges carry the same load, but the one built with more redundant supports keeps standing after the same number of beams fail.
Core 1 and Core 2 biomarkers
In the 2024 criteria, Core 1 biomarkers turn abnormal early — amyloid PET, approved spinal fluid tests, and accurate plasma tests, especially p-tau217 — and an abnormal Core 1 result is enough to say Alzheimer's pathology is present. Core 2 biomarkers, such as tau PET and MTBR-tau243, turn abnormal later and are used to stage how far the biology has progressed and to gauge prognosis.
FDG-PET
FDG-PET injects a radioactive form of glucose and maps how much sugar different brain regions are using, which reflects how actively they are working. In dementia it shows patterns of reduced activity that can help distinguish Alzheimer's from frontotemporal dementia. It measures neurodegeneration in general and is not specific to any one protein.
Functional MRI (fMRI)
Functional MRI is a specialised form of MRI that observes which brain areas become more active — consuming more oxygen — during particular mental tasks. It is mainly a research tool for understanding how the brain is organised; it is not used to diagnose Alzheimer's disease in ordinary clinical practice.
Glial fibrillary acidic protein (GFAP)
GFAP is a protein released by astrocytes, the brain's support cells, when they are activated by injury or inflammation. It is measured in blood as a marker of the inflammatory response in Alzheimer's disease. It is not specific to Alzheimer's — it rises in many brain conditions, so it is placed in the 'I' (inflammation) category rather than among the core Alzheimer's markers.
Hippocampus
The hippocampus is a seahorse-shaped structure deep in each temporal lobe that is essential for forming new memories. It is one of the earliest regions damaged in typical Alzheimer's disease, which is why recent events are forgotten while memories from decades ago remain. It is the brain's 'save' button. When it fails, old files are still readable but new ones never get written to disk.
Lumbar puncture
A lumbar puncture, or spinal tap, is a procedure in which a thin needle is inserted between two vertebrae in the lower back to collect a small sample of cerebrospinal fluid. It is done below where the spinal cord ends, and the most common after-effect is a headache.
Magnetic resonance imaging (MRI)
MRI uses a powerful magnet, radio waves, and a computer to produce detailed pictures of structures inside the body without using ionising radiation. In dementia care it shows the pattern and degree of brain shrinkage, detects strokes and small-vessel damage, and is the required monitoring test for ARIA during anti-amyloid treatment. The strong magnetic field means implants and metal must be declared beforehand.
Mini-Mental State Examination (MMSE)
The MMSE is a brief screening test of orientation, recall, attention, language, and copying, scored out of 30. It is a screen, not a diagnosis: scores are affected by education, language, hearing, and vision, and a normal score does not rule out early impairment.
Montreal Cognitive Assessment (MoCA)
The MoCA is a short cognitive screening test scored out of 30 that includes more demanding executive-function and attention items than the MMSE, making it somewhat better at picking up mild cognitive impairment. Like any screen, it indicates whether fuller assessment is warranted, not what the cause is.
Neurofilament light chain (NfL)
NfL is a structural protein from inside nerve fibres that leaks into spinal fluid and blood when neurons are damaged. It is a sensitive marker that something is injuring nerve cells, but it says nothing about what — it rises in Alzheimer's, in other dementias, after head injury, and in multiple sclerosis alike. NfL is debris in the river. It proves something upstream is breaking apart; it does not tell you what.
Neuropsychological testing
Neuropsychological testing is a structured set of pencil-and-paper and computer tasks that measure memory, language, attention, visual-spatial skill, and executive function against what is expected for a person's age and education. It gives a far more detailed picture than a short screening test and can help distinguish between dementia types, depression, and normal ageing.
p-tau217
P-tau217 is a form of the tau protein with a phosphate attached at position 217. Its level in blood or spinal fluid rises early in Alzheimer's disease, around the same time amyloid PET turns abnormal and well before tau PET does. The 2024 criteria list plasma p-tau217 as the blood test accurate enough to be used for diagnosis on its own among Core 1 markers. It is a smoke alarm rather than a photograph of the fire: it tells you the process is under way, long before you could see the damage.
Positron emission tomography (PET)
PET is a nuclear medicine scan in which a radioactive tracer is injected into a vein and a scanner tracks where it goes in the body. The tracer determines what the scan shows — one tracer maps glucose use, another binds amyloid, another binds tau. PET shows how tissue is functioning or what it contains, rather than just its shape. MRI photographs the building. PET releases a dye into the plumbing and watches where it pools.
Standardised uptake value ratio (SUVR)
SUVR is a way of quantifying a PET scan by comparing how much tracer is retained in the brain regions of interest against a reference region expected to be free of the pathology, such as the cerebellum. It turns a picture into a number that can be tracked over time.
Subjective cognitive decline
Subjective cognitive decline is when a person notices their own memory or thinking getting worse, but standard cognitive tests still come back in the normal range. For some people it is an early signal of underlying disease; for many others it reflects stress, poor sleep, mood, or normal ageing.
Tau
Tau is a protein that normally helps stabilise the internal transport structures of nerve cells. In Alzheimer's disease it becomes abnormally modified and clumps inside neurons as tangles. Tau spread across the brain tracks much more closely with the timing and location of symptoms than amyloid does. Tau is like the rails inside a cell. When the rails collapse, nothing gets delivered and the cell starves.
Tau PET
Tau PET uses a tracer such as flortaucipir that binds to aggregated tau, showing where tangles have accumulated. It turns abnormal later than amyloid PET, and because tau spread tracks symptoms closely, it is used mainly for staging how far the disease has progressed and for prognosis rather than for initial diagnosis.
White matter hyperintensities
White matter hyperintensities are bright patches on certain MRI sequences in the brain's wiring tracts. They have long been read as small-vessel ischaemic damage, but they can also reflect axon damage, autoimmune demyelination, or leaky blood-brain barrier from cerebral amyloid angiopathy — so they are a signal to investigate, not a diagnosis in themselves.

Missing a term you'd like explained? Ask us to add it.

What the research library says

Each page below is built from the studies in alzhub's library: how many match, what kinds of study they are, and what the papers report in their own words.

What's the difference between Alzheimer's and dementia?

Dementia is the umbrella term, not a specific disease. The NIA defines it as “the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities.” Alzheimer's is one cause of dementia; others include Lewy body dementia, frontotemporal disorders and vascular dementia, and it is common for a person to have more than one type at once (“mixed dementia”). Telling which cause is behind someone's dementia takes a proper assessment: what a memory-clinic workup can involve.

Worldwide, the World Health Organization estimates Alzheimer's disease “may contribute to 60–70% of cases” of dementia. (NIA) (WHO dementia fact sheet, updated 3 July 2026)

What is a biomarker?

A biomarker is something that can be measured in the body, such as a protein in blood or spinal fluid or a pattern on a brain scan, that shows a disease process is under way. In Alzheimer's research the main ones measure amyloid and tau. Alzheimer's biomarkers compares the tests, and the p-tau217 blood test covers the newest one.

What is mild cognitive impairment, and does it always turn into Alzheimer's?

No, it does not always. MCI means someone has more memory or thinking problems than is normal for their age, but the symptoms do not yet interfere with everyday life. The NIA reports that an estimated 10–20% of people age 65 or older with MCI develop dementia over a one-year period — which also means most do not, in any given year.

The NIA is explicit that “not everyone who has MCI develops dementia. In many cases, the symptoms of MCI may stay the same or even improve.” Why some people progress and others do not is still being worked out; one part of the answer is the cause behind the symptoms, which a memory-clinic assessment can look into. How accurate are the memory tests used in that assessment? (NIA: What Is Mild Cognitive Impairment?)

Last updated